Elanco Animal Health Incorporated Contract Liability (Deferred Revenue)
Elanco Animal Health Incorporated (ELAN) had Contract Liability (Deferred Revenue) of $450.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $450.00M.
- 2026-03-31: Contract with Customer, Liability, Current $400.00M.
- 2025-12-31: Contract with Customer, Liability, Current $416.00M.
- 2025-09-30: Contract with Customer, Liability, Current $376.00M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $450.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $400.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $416.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $376.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $367.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $319.00M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $332.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $333.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $356.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $318.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $367.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $356.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $332.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $329.00M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $324.00M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $298.00M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $284.00M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $295.00M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $319.00M 10-K · filed 2023-03-01 | $316.00M 10-K · filed 2022-02-28 |
| 2021-09-30 | $316.00M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $303.00M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $331.00M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $295.00M 10-K · filed 2022-02-28 | $295.30M 10-K · filed 2021-03-01 |
| 2020-09-30 | $278.60M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $164.00M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $192.70M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $211.00M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $182.20M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $176.00M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $171.70M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $169.90M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $147.90M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $165.50M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |